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ABSTRACT 
Objective: Bioflavonoid hesperidin is used primarily to assist treatment of capillary disorders like hemorrhoids and varicose veins, by reducing 
capillary permeability. There are certain limitations to the use of these bioflavonoid in the pharmaceutical formulations because of their physical 
properties like limited aqueous solubility, poor bioavailability and high oral dose. Therefore in the present research work micro emulsions of 
hesperidin were developed for improving solubility and bioavailability using topical route.  
Methods: Micro emulsions of hesperidine were prepared by plotting pseudo ternary phase diagram using eucalyptus oil, Tween 80, AccononCC6 
and water. The micro emulsion with optimized droplet size, polydispersity index and ex vivo diffusion ability was then converted into the ointment 
for ease of application. Droplet size and Polydispersity index were obtained by using Photon correlation spectroscopy. Optimized o/w 
microemulsion of hesperidin composed of eucalyptus oil 20%, Tween-80/Acconon CC-6(2:1) 33% and water was then converted into ointment 
using optimized ointment base.  The microemulsion loaded ointment was then characterized for physicochemical parameters. Ex-vivo permeation 
and In-vivo bioavailability studies were carried out to check the r. release profile of drug from the prepared formulations. 
Results: It was observed from ex-vivo permeation studies that flux value for optimized microemulsion was found to be 8.971µg/ml/cm2as 
compared to pure hesperidin (1.230 µg/ml/cm2). This formulation was then converted into ointment by using optimized base containing PEG-6000, 
PEG-400 and Cetyl alcohol. This microemulsion based ointment passed all the characterization tests (droplet size analysis using PCS, ex-vivo 
permeation studies, in-vivo bioavailability studies etc.) as well as remained stable for the period of 3 mo during stability studies as per ICH 
guidelines. The bioavailability studies of hesperidin microemulsion based ointment in rats showed 3 fold statistically significant (p<0.001) 
improvement in bioavailability as compared to microemulsion when applied topically.  
Conclusion: Thus it can be concluded that components of microemulsion and ointment are contributing to improve bioavailability of hesperidin.  
Keywords: Hesperidin, Bioflavonoid, Venous disease, Microemulsion, Topical, In-vivo bioavailability. 
 
INTRODUCTION 
Hesperidin is the major flavanone glycoside in sweet orange and 
lemon obtained as an abundant byproduct of Citrus cultivation [1, 
2]. Hesperidin has antioxidant, anti-inflammatory, hypolipidemic, 
vasoprotective, and cholesterol-lowering properties [3] and it plays 
important role in the inhibition of enzymes involved in several 
diseases like phospholipase A2, lipoxygenase [4]. It is known to 
reduce permeability and fragility of capillary walls [2]. The 
bioavailable formulations of this bioflavonoid may prove to be an 
effective treatment for many blood vessel disorders like hemorroids, 
varicose veins, venous stasis etc. In all these diseases proper 
therapeutic treatment is not widely available. As a result patient 
suffers silently until the disease aggravates to the level of surgery. 
For improving therapeutic efficacy of hesperidin it is required to 
identify the problems associated with its bioavailability in order to 
develop various formulations which can prove to be effective to 
treat moderate symptoms of venous diseases at an early stage. 
Hesperidin is reported to be unstable at gastric pH where it undergoes 
hydrolysis into aglycone hesperetin and enzymatic degradation. 
Moreover, probably due to its crystalline state, this flavonoid is slightly 
soluble in water [5], a characteristic which leads to a very low 
dissolution rate and an irregular absorption from oral solid dosage 
forms in the gastrointestinal tract (oral bioavailability<25%) [2]. 
Literature reports few attempts made to improve oral bioavailability 
of hesperidin by preparing oral formulation containing spray dried 
gastro-resistant microparticles [6]. 
It is also evident from the literature that when poorly soluble actives 
have bioavailability problems through oral route, the molecules 
show good permeability through lipophilic membranes like skin [7]. 
Rate limiting step for drug permeation is poor drug dissolution i.e. 
dissolution of actives from formulation is not fast enough to replace 
permeated molecules which affects the permeation rate [8]. As only 
dissolved fraction of drug in the vehicle can enter the skin, solubility 
of the drug in the vehicle is an important aspect in the formulation of 
topical dosage forms [9]. 
Therefore in the present research work attempt has been made to 
develop a novel topical formulation of hesperidin having better 
solubility in the vehicle as well as good permeation ability through 
the skin to show venoprotective effect. It was thought that topical 
formulation will improve the patient compliance as a chronic 
treatment for mild to moderate symptoms of venous diseases.  
It is a challenge to develop a topical formulation with enhanced 
permeation ability, high drug-loading capacity and less skin 
irritation. Microemulsions have been visualized as superior drug 
carriers because of its several permeation enhancement 
mechanisms such as an increased concentration gradient and 
thermodynamic activity towards skin as well as the permeation 
enhancement activity of the components [10].  
High solubilization capacity of microemulsion helps in improving 
bioavailability of poorly soluble drugs. Literature reports 
microemulsions as efficient vehicles for the topical delivery of 
poorly soluble drugs such as triptolide and estradiol [10, 11]. 
In the present work hesperidin o/w microemulsions were prepared 
using various oils and were characterized for droplet size as well as 
other physical parameters and were converted into ointment so that 
they gain suitable viscosity for topical application of hesperidin.  
The in-vitro permeation study was carried to evaluate the effect of 
microemulsion components and ointment bases on permeability of 
the drug through excised rat skin. In-vivo permeation studies were 
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carried out on rats to determine bioavailability of hesperidin by 
topical application. 
MATERIALS AND METHODS 
Materials 
Hesperidin was purchased from Aaisland Chemical Products, 
Aurangabad, India. Soyabean oil, eucalyptus oil were acquired from 
Research lab Fine chemical industries, Mumbai. Tween 80, PEG-
1500, PEG-400 and Cetyl alcohol were obtained from Loba Chemie, 
Mumbai, India. Acconon CC-6 (ethoxylated caprylic and capric 
glycerol esters) was a gift sample provided by Abitec Corporation, 
Janesville, WI. USA. 
Formulation of o/w microemulsion of hesperidin 
Various oils like soybean oil, eucalyptus oil, surfactants and co 
surfactants were screened for hesperidin solubility in order to 
formulate hesperidin o/w micro emulsion. Suitable concentration 
ranges of components for the existence in micro emulsion region 
were obtained by constructing pseudo ternary phase diagrams fig. 
(1) Using water titration method at ambient temperature. 
According to the micro emulsion regions in the phase diagrams 
formulations were prepared (table 1) and were characterized for 
transmittance and visual clarity, viscosity, droplet size and electrical 
conductivity (table 3). Micro emulsions passing characterization 
tests were selected for drug loading.  
Drug loading was carried out by adding excess amount of hesperidin 
to each of the selected micro emulsion (5 ml) in a stoppered vial. The 
vials were then equilibrated at 37±1.0 °C in a water bath shaker 
(Remi, Mumbai India.) for 72 h and subsequently centrifuged at 3000 
rpm for 15 min. The supernatant was filtered through a 0.45 μm 
membrane filter. The concentration of hesperidin was determined 
by UV spectrophotometer at 285 nm. Each experiment was carried 
out in triplicate and results were expressed as mean±standard 
deviation (table 2). 
  
Table 1: Composition of microemulsion formulations 
% Composition Formulation code (Quantities in percent) 
E 1 E 2 E 3 E 4 
Eucalyptus oil 20 25 10 5 
Tween 80 22 20 24 28 
Acconon-cc-6 11 10 12 14 
Water 47 45 54  53 
  
Table 2: Drug loading of optimized micro emulsions 
Formulation code Drug loading (mg/ml) 
E 1  18.6±0.7 
E 2 13.8±0.2 
E 3 11.3±0.3 
E 4 11.7±0.5 
(mean±SD, n=3) E1-(micro emulsion containing 20% eucalyptus oil, s-cos ratio 2:1), E2 (micro emulsion containing 25% eucalyptus oil, s-cos ratio 
2:1), E3 (micro emulsion containing 10% eucalyptus oil, s-cos ratio 2:1), E4 (micro emulsion containing 5% eucalyptus oil, s-cos ratio 2:1) 
 
Drug loaded microemulsions were subjected to droplet size analysis 
by using Photon Correlation Spectrometer (DTS version 5.10 beta 1, 
serial No. MAL501131, Malvern Instruments Ltd.). Samples were 
loaded into 1 cm2 cylindrical cuvettes and placed in a thermostated 
scattering chamber. The aperture of the photomultiplier tube was 
set at 50 nm.  
Ex-vivo skin permeation studies of all the drug loaded 
formulations were carried out using Franz diffusion apparatus 
fitted with the abdominal skin of excised male Sprague-Dawley 
rats weighing 200-250 g. Saturated solution of hesperidin in pH 
7.4 phosphate buffer was used as a control for comparison with 
ex-vivo permeation rates of hesperidin microemulsions. Data 
obtained from the analysis was further analysed to determine the 
permeation rate at steady state (Jss, μg/cm2/h) and Permeability 
coefficient (Kp cm/h). 
Preparation of micro emulsion based ointment (MBO) of 
hesperidin  
Optimized microemulsion formulations were converted into 
ointment for attaining suitable viscosity which subsequently 
improves applicability of the formulation. For the preparation of 
MBO, water soluble ointment bases were used which consists of 
carbowaxes. The most suitable carbowax ointment bases contain 
heavy and light molecular-weight polyethylene glycols. Ointment 
base formulae containing mixture of various grades of Polyethylene 
glycols (PEGs) were physically evaluated.  
The formula showing better physical properties and stability was 
selected for incorporation of microemulsion (table 4). Ointment 
base containing Polyethylene Glycol 1500 (47.5%), Polyethylene 
Glycol 400 (47.5%) and Cetyl Alcohol (5.0%) was prepared by fusion 
method [12]. The hesperidin microemulsion was added to the 
ointment base (1 ml/g) on an ointment slab and mixed using spatula 
to ensure uniform mixing.  
Characterization of microemulsion based ointment 
Evaluation of pH and viscosity 
The pH values were evaluated at 25 °C by using a LI120 digital pH 
meter (Elico, pH meter, Type 003). The pH of the formulations was 
measured by mixing 5 g of MBO in 45 ml of water. The pH of the 
formulations should be compatible with that of the skin in order to 
avoid skin irritation. 
Viscosity of the MBO was measured using Brookfield DV-II+Pro 
viscometer. Experiments were carried out in triplicate for each 
sample, and the results are expressed as an average±standard 
deviation. 
Analysis of drug content 
Accurately weighed 1g of MBO sample was transferred to 10 ml 
volumetric flask and volume was adjusted using Dimethyl 
Sulphoxide. The resulting solution was filtered using 0.45 µm filter. 
1 ml of filtrate was pipette out and was transferred to 50 ml 
volumetric flask to make up the volume using phosphate buffer (pH 
7.4). This solution was then analyzed at 285 nm using UV 
Spectrophotometer to determine the content of hesperidin in the 
formulation.  
Extrud ability 
Extrudability of MBO formulations was determined using a closed 
collapsible tube containing 20 g of MBO. The tube was pressed 
firmly at the crimped end and a clamp was applied to prevent any 
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rollback. The cap was removed and the MBO was extruded until the 
pressure was dissipated. 
Spread ability 
Spread ability of the MBO formulation was determined by an 
apparatus which consists of a wooden block with pulley at one end. 
A rectangular ground glass was fixed on this block. An ointment 
(about 3 g) was placed on this ground plate and was sandwiched 
using another glass plate having the dimension as that of the fixed 
ground plate which was provided with the hook. 1 Kg weight was 
placed on the top of the plate for 5 min to expel air and to provide a 
uniform film of the ointment between the plates. The top plate was 
then subjected to pull off 80 g weight with the help of string attached 
to the hook and the time (in seconds) required by top plate to cover 
a distance of 10 cm was noted. A shorter interval indicates better 
spread ability [13]. Spread ability is given in unit g. cm/sec and was 
determined by the following formula- 
S= M x L/T 
Where, L= length moved by glass slide 
T= Time in sec 
M=Weight in pan  
S= Spread ability  
Ex-vivo permeation study 
Ex-vivo skin permeation studies on micro emulsion and MBO 
formulations were performed using Franz diffusion apparatus fitted 
with the abdominal skin of excised male Sprague-Dawley rat 
weighing 200-250 g. Before using rat skin was cleaned and washed 
with saline. It was mounted on the receptor chamber of the diffusion 
cell assembly having effective diffusion area of 3.14 cm2which was 
filled using 20 ml of pH 7.4 phosphate buffer saline (PBS). Accurately 
weighed 1g of formulation was applied on the epidermal surface of 
the mounted rat skin. The receptor fluid was continuously stirred 
using small magnetic bar and the temperature was maintained at 
37˚C±1˚C. An aliquot of 1 ml of sample was withdrawn after each 
interval and the same amount of fluid was replaced using fresh 
phosphate buffer pH 7.4. Collected samples were filtered through 
0.45μm filter and hesperidin was quantified by using UV 
spectrophotometer at 285 nm. Saturated solution of hesperidin in 
pH 7.4 phosphate buffer was used as a control since topical 
marketed formulation of hesperidin was not available. Each 
experiment was carried out in triplicate and the results were 
expressed as an average±standard deviation (fig. 2, table 6). 
Stability studies 
Three batches of each formulation were filled in sealed glass 
containers and kept in stability chamber (Remi, India) at 40±2 °C 
(75±5% RH) and 25±2 °C (60±5% RH) for three months. The 
stability of the formulations was checked periodically with respect 
to appearance, pH, viscosity, spread ability, extrude ability and 
drugcontent. 
In-vivo bioavailability study  
The animal study protocol was reviewed and approved by the 
Institutional Animal Ethical Committee, Gurunanak College of 
Pharmacy (Regd no. 675/02/C/CPCSEA, Dated-13/09/07), RTM 
Nagpur University, India. Male Wistar strain rats of both sexes were 
selected for the study. All the experimental rats were housed in 
cages, with access to food and water ad libitum until use. 24 h prior 
to the experiment the dorsal skin of rats were shaven to remove hair 
and washed with physiological saline solution. Animals were 
grouped as Group1, Group 2 and Group 3 containing 12 animals 
each. Accurately weighed 1 g of micro emulsion (drug content 0.8%, 
w/w), MBO (drug content 0.8%, w/w) was applied on the dorsal 
surface of the rat skin (1.76 cm2) for Group 1 and Group2 
respectively. Ointment containing thoroughly mixed hesperidin 
powder was used as a control and was applied to animals in Group 3 
(1g equivalent to 0.8%w/w hesperidin). One animal was used as a 
blank control. After application of formulations, blood samples were 
withdrawn by retro-orbital technique at regular intervals. Each time 
1-1.2 ml of blood was withdrawn and allowed to clot. The blood 
samples were then centrifuged for 10 min at 4000 rpm. The 
separated plasma was transferred to clean micro-centrifuge tubes 
and stored at −20  °C. The amount of hesperidin in the samples was 
estimated using HPLC. 
HPLC analysis of plasma sample 
Hesperidin concentration in plasma sample was determined by 
HPLC using (Agilent 1000 series USA), an Agilent G1314A Variable 
wavelength detector set at 285 nm and column Eclipse XDB-C18 (5 
µm, 150 mm×4.6 mm). The mobile phase was a mixture of methanol: 
water (40:60), pH adjusted to 4.5 by acetic acid. The mobile phase 
was filtered through a 0.45 µm membrane filter and pumped from 
the filter reservoir at a flow rate of 1 ml/min which yielded a column 
back pressure of 110-120 bars. The run time was set at 5 min and 
the volume of injection was 20 µl. The column was equilibrated for 
at least 30 min with the mobile phase running through the system 
before injecting the drug solution. Then the phase separated sample 
was diluted with the mobile phase filtered through sample filter and 
injected into the column. The eluent was monitored by isocratic 
elution at 285 nm [14]. 
Pharmacokinetic analysis 
The area under the plasma concentration-time curve from the time 
of drug administration to the last quantifiable concentration (AUC0-t) 
was calculated by linear trapezoidal integration.  
Skin irritancy study 
To assess the skin-sensitizing potential of hesperidin micro 
emulsion and MBO skin irritancy studies were carried out on rats. 
The formulations were applied on dorsal side of shaven skin and the 
site of application was occluded with gauze and covered with a non-
sensitizing micro-porous tape. Erythema values for formulations 
with and without pretreatment with abrading ointment were 
recorded. The patch was removed after 24 h and the score of 
erythema was recorded as follows: no erythema-0; mild erythema-1; 
moderate erythema-2; severe erythema-3. Eventually, the total 
scores for irritation test in each condition were calculated using the 
following equation [15]. 
 
RESULTS AND DISCUSSION 
Formulation of o/w micro emulsion 
It was observed from the results of screening studies that hesperidin 
showed maximum solubility in Eucalyptus oil (26.27±0.235 mg/ml). 
Out of various surfactants and co surfactants non-ionic surfactant 
Tween-80 and co surfactant Acconon CC-6 showed highest solubility 




Fig. 1: Pseudoternary phase diagram of the system containing 
Eucalyptus oil, Tween 80 and Acconon CC-6 (2:1) 
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Therefore these components were used to plot pseudo ternary 
phase diagrams using various ratios of Tween-80 and Acconon CC-6. 
From fig. (1) it was observed that in phase diagram constructed 
using 2:1 ratio of surfactant–co surfactant larger isotropic region 
existed. As a result micro emulsion formulations were chosen as 
shown in table (1) from phase diagram plotted using Eucalyptus oil 
and surfactant: co surfactant ratio (2:1). 
Characterization of microemulsions 
All the prepared microemulsion formulations passed visual clarity 
test and showed 100% transmittance as seen from table (3). It was 
observed that formulation E1 has viscosity 40.2 cps and droplet size 
33.12±2.31 nm which is very small as compared to the other 
formulations. All the formulations passed electrical conductivity test 
confirming formation of o/w microemulsion. Polydispersity index 
suggests uniformity of droplet size within all the formulations. pH 
values of all the formulations were nearly in the neutral region 
suitable for topical application. 
Drug loading of micro emulsions 
As all the above formulations passed the evaluation tests and having 
droplet sizes below 100 nm. These formulations were loaded with 
the drug for further evaluation. Formulation E1 showed highest drug 
loading (18.6±0.7 mg/ml) as seen from table (2). 
 
Table 3: Physicochemical parameters of t micro emulsion formulations 
Formulation Code Electrical Conductivity (µS/cm)* Viscosity (cps)* Droplet size 
(nm)* 
Polydispersity Index pH 
E 1 173.5±1.3 40.2±1.2 33.12±2.3 0.3 6.4 
E 2  106.9±1.4 37.5±1.5 96.8±1.1 0.5 6.7 
E 3 104.2±2.0 58.3±0.1 85.76±1.1 0.9 6.2 
E 4 132.2±2.3 46.1±0.9 78.64±1.1  0.5  6.6 
*All values are represented as mean±SD, n=3. 
 
Table 4: Physicochemical parameters of the drug loaded micro emulsions 
Formulation Code Viscosity (cps) Droplet size (nm)* Polydispersity Index 
E 1 37.9 49.10±1.3  0.3 
E 2 39.4 106.13±2.1  0.3 
E 3 59.6 95.67±2.8  0.7 
E 4 60.7 84.89±2.9  0.3 
*All values are represented as mean±SD, n=3 
 
Characterization of drug loaded micro emulsions 
Measurement of viscosity, droplet size and polydispersity 
Drug loaded microemulsion formulations were subjected to 
determination of viscosity, droplet size and droplet size distribution 
i.e. polydispersity index to know the effect of addition of drug to the 
microemulsion formulations. Results are shown in table (4). It was 
observed that viscosity as well as droplet size increased due to 
addition of the drug. As the drug incorporated in the microemulsion 
is less water soluble drug it must be finding its site for solubilization 
in the oil droplets.  
Also the solubilizing power of the microemulsion components the 
unique structural organization of the microemulsion can add 
solubility regions and thus increasing the loading capacity of 
microemulsion [16]. This might be the possible reason for increase 
in droplet size of the o/w microemulsion as a result of drug loading. 
Ex-vivo skin permeation studies 
The permeation ability of various microemulsions was evaluated by 
carrying out ex-vivo permeation studies. It was observed from the 
results that formulation E1 showed highest flux value (8.971 
μg/cm²/h) as compared to other o/w eucalyptus oil microemulsion 
formulations of hesperidin (p<0.05). The reason might be higher 
drug loading in the formulation resulting in maintenance of 
concentration gradient for the diffusion of hesperidin through rat 
skin. Also droplet size of this formulation was smallest i.e. 49.10 nm. 
Presence of droplets of the microemulsion of only a few nanometers 
in size has a significant contribution to the percutaneous 
penetration of drug [9]. From the above results formulation E1 
(containing 20% eucalyptus oil and 33% Tween 80: Acconon CC-6 
mixture 2:1) was selected for the preparation MBO. 
Preparation of microemulsion based ointment (MBO) 
In order to improve topical applicability of the prepared hesperidin 
micro emulsion as well as to further improve permeation rate 
various water soluble ointment bases were investigated. As the drug 
is embedded in oil droplets of the o/w micro emulsion choice of 
water soluble base was thought to be appropriate for incorporating 
micro emulsion in the base to adjust the consistency and 
applicability of the microemulsion.  
Combination of PEG 6000: PEG 400: Cetyl alcohol (47.5%: 
47.5%:5%) and combination of PEG 1500: PEG 400: Cetyl alcohol 
(47.5%:47.5%:5%) were found to be the best as their consistency 
and texture was excellent. Ointment bases were prepared by fusion 
method. To the prepared ointment base microemulsion was added 
(1 ml/g) and mixed on ointment slab using spatula. 
Physicochemical characterization of MBO 
The excellent the extrude ability the better is the applicability of the 
formulation. Spread ability denotes the extent of area to which the 
readily spreads on application to the skin or the affected part. The 
efficacy of the formulation or the bio-availability of the ointment 
also depends on the spread ability value. The higher the value of 
spread ability of the ointment the higher the bioavailability of the 
formulation [17]. It was observed from table (5) that formulation 
MBO1 (PEG6000:PEG400: Cetyl alcohol 47.5%:47.5%:5%) has 
excellent extrude ability and spread ability as well as suitable pH for 
the topical application. Therefore this formulation was selected for 
further evaluations. Drug content of MBO formulations ranged 
between 96-98%. 
Ex-vivo permeation study of MBO 
Ex-vivo permeation studies on prepared MBO formulations were 
carried out using excised rat skin to study the influence of 
components of ointment base on the permeation profile of 
hesperidin micro emulsion. 
Therefore release rates of MBO were compared with optimized 
hesperidin micro emulsion E1 and saturated solution of hesperidin 
in pH 7.4 phosphate buffers was used as a control. It was observed 
from fig.(2) and table (6) that formulation MBO1 has highest 
permeation rate 26.91 µg/cm2/h as compared to MBO2, micro 
emulsion E1 (p<0.001) and control. The high permeation rate of 
MBO1 could be attributed to high drug loading resulting in the 
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maintenance of high concentration gradient across the skin as well 
as the presence of Cetyl alcohol in ointment base which enhances 
penetration of topically applied drugs by physically altering the 
epidermis. It acts as a permeation enhancer by altering the 
intercellular lipid shape and extracting lipids from stratum corneum 
which increases penetration [18]. Polyethylene glycol base used in 
the formulation is suitable for biological applications because it is 
soluble in water and therefore it enhances the solubility of 
hydrophobic drugs [19]. Also the MBO acts as a drug reservoir 
where drug is released from the inner phase to the outer phase and 
then further onto the skin [10]. Very small size of oil droplets in the 
MBO which contains drug could easily cross the skin barrier to 
release drug to the required site. Presence of eucalyptus oil in the 
micro emulsion which acts as a permeation enhancer might be one 
more reason for enhancement of permeation rate of drug through 
the skin [20, 21]. 
 
Table 5: Composition and physicochemical parameters of formulated MBO 
Formulation 
code 





MBO1 PEG6000:PEG400:Cetyl alcohol 
(47.5%:47.5%:5%) 
E 1 7.2 18,000±5.00  6.1±0.02 +++ 
MBO 2 PEG 1500: PEG 400: Cetyl alcohol 
(47.5%:47.5%:5%) 
6.7 14,410±12.00  5.5±0.1 ++ 
* ME-Micro emulsion,+++Excellent,++Good, E1-Optimized hesperidin micro emulsion, -**All values are represented as mean±SD, n=3. 
 
 
Fig. 2: Permeation profiles of hesperidin MBO formulations and 
micro emulsion–--All values are represented as (mean±SD, n=3) 
 
(47.5%:47.5%:5%) as a base,MBO2-Micro emulsion Based Ointment 
containing PEG 1500: PEG 400: Cetyl alcohol (47.5%:47.5%:5%), 
E1-optimized micro emulsion containing 20% eucalyptus oil, 22% 
Tween 80, 11% Acconon CC-6 and 47%water. Control–saturated 
solution of hesperidin in pH 7.4 buffer. 
Stability studies of MBO 
From the study it was found that all the formulated MBO were stable 
at 40±2 °C (75±5% RH) and 25±2 °C (60±5% RH) for 3 mo as seen 
from table (7). No drastic change in color, appearance and pH was 
observed. The drug content of the final formulation was found to be 
in the acceptable limit i.e.96-99%. 
 
Table 6: Permeation parameters of MBO 
Formulation Code Jss (µg/cm2/h) Kp× 10-3 (cm/h) 
MBO 1 26.9 1.4 
MBO 2 19.1 1.0 
E1 8.9 0.5 
Control  2.2 0.1 
MBO1–Micro emulsion Based Ointment containing PEG6000: 
PEG400: Cetyl alcohol. 
 
Table 7: Stability study data of MBO formulations 
Formulation code Time (month) pH Appearance Viscosity (cps) % Drug content 
MBO 1 
40±2 °C (75±5% RH) 
0 7.2±0.2 CLEAR 18,000±1000 100.0 
1 7.11±0.1 CLEAR 17,900±500 98.90±0.5 
2 7.08±0.16 CLEAR 17,600±350 97.03±0.30 
3 7.08±0.00 CLEAR 17,600±600 97.00±0.10 
MBO 1 
25±2 °C (60±5% RH) 
0 7.2±0.2 CLEAR 18,000±350 100.0 
 1 7.08±0.12 CLEAR 17,800±1000 98.34±0.1 
2 7.01±0.21 CLEAR 17,580±350 97.19±0.5 
3 7.00±0.13 CLEAR 17,510±400 97.10±0.1 
MBO 2 
40±2 °C (75±5% RH) 
 
0 6.7±0.21 CLEAR 14,410±700 100.0 
1 6.5±0.12 CLEAR 14,300±500 98.57±0.5 
2 6.5±0.12 CLEAR 14,250±250 97.08±0.35 
3 6.5±0.3 CLEAR 14245±250 96.78±0.5 
MBO 2 
25±2 °C (60±5% RH) 
0 6.7±0.2 CLEAR 14,410±400 100.0 
1 6.6±0.2 CLEAR 14,320±300 97.82±0.15 
2 6.5±0.12 CLEAR 14100±100 96.73±0.30 
3 6.5±0.2 CLEAR 14100±100 96.00±0.10 
-All values are represented as mean±SD, n=3 
 
In-vivo bioavailability studies 
The results of the bioavailability study as shown in fig.(3), table (8) 
indicate that hesperidin is released and permeated well from the 
MBO when applied topically as compared micro emulsion E1. The 
Cmax of hesperidin after topical application of hesperidin MBO and 
micro emulsion was found to be 30.3 and 11.3 µg/ml respectively.  
MBO1–Micro emulsion Based Ointment containing PEG6000: 
PEG400: Cetyl alcohol 
(47.5%:47.5%:5%) as a base, ME1-optimized micro emulsion 
containing 20% eucalyptus oil, 22%Tween80,11%AccononCC-6 and 
47%water, Ointment(pure hesperidin)-containing 18.5 mg of 
hesperidin), Control–saturated solution of hesperidine in pH 7.4 
buffer. 
-All values are represented as mean±SD, n=3 
Significant difference in the Cmax values was observed for MBO as 
well as micro emulsion and simple ointment. The Tmax value for all 
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the formulations was found to be 4h, since the route of 
administration was topical for all the formulations. The overall mean 
value of AUC (0-8) for hesperidin MBO was significantly greater than 
the microemulsion of hesperidin demonstrating improved 
bioavailability when microemulsion was converted into ointment. 
 
 
Fig. 3: Plasma drug concentration-time profile of hesperidin 
MBO and micro emulsion 
 
It is clearly evident from the results that components of micro 
emulsion and MBO have significant contribution in improving the 
bioavailability of hesperidin. It is also reported in the literature that 
hesperidin itself enhances epidermal permeability barrier 
homeostasis to certain extent due to stimulation of epidermal 
proliferation, differentiation, as well as lamellar body secretion [22]. 
Therefore it can be concluded that topical formulations of 
hesperidin with improved bioavailability can be prepared by 
adopting this novel technique for the treatment of venous diseases 
i.e. to assist the treatment of capillary disorders like haemorrhoids 
and varicose veins by reducing capillary permeability. 
Skin–irritancy studies 
The results of skin irritation test are shown in table (9). The 
intensity criterion of skin irritation followed the protocol that scores 
of<0.5 meant no irritation, 0.5–3 for slight irritation,>6 showed 
severe irritation and others were moderate irritation. It was 
observed that when MBO and micro emulsion formulations were 
applied to the normal rat skin no irritation observed i.e. all the 
scores were below 0.5. Whereas when formulations were applied to 
the damaged rat skin micro emulsion formulation (ME) showed 
slight irritation. The possible reason might be the decreased 
metabolic capability for damaged skin induces accumulation of 
surfactant mixture and oil phase, which led to occurrence of 
irritation reaction [22]. Therefore, it could be concluded that MBO 
showed no irritation to intact skin under the conditions of the study 
and these findings might be due to the change of micro emulsion 
property after adding PEG ointment base. The network structure 
formed and the increase of the viscosity decreased the contact 
chances between skin and micro emulsion. Thus it can be said that 
the skin irritation by MBO was negligible. 
 
Table 8: Pharmacokinetic parameters of hesperidin MBO, microemulsion and ointment containing hesperidin powder (each containing 
18.5 mg of hesperidin) 
Pharmacokinetic parameter  MBO  Microemulsion   Ointment   
Cmax(µg/ml)   30.3±0.1 11.3±0.2  3.5±0.1  
Tmax(h)   4.0±0.5 4.0±0.01  4.0±0.01  
AUC(0-8)(µg/ml)   66.7±0.2 43.26±0.1  12.1±0.1  
Relative Bioavailability (%)   154.3±0.1 -----    
-All values are represented as mean±SD, n=3 
 
Table 9: Average response scores of skin irritation for single application 
Animal group F. code 1 h 2 h 3 h 4 h 
Normal skin ME 0.6 0.25 0.0 0.0 
MBO 0.25 0.0 0.0 0.0 
Damaged skin ME 0.8 0.4 0.0 0.0 
MBO 0.4 0.1 0.0 0.0 
-All values are represented as mean, n=3. 
 
CONCLUSION 
A novel micro emulsion based topical formulation of hesperidin with 
suitable viscosity and spread ability was formulated which showed 
significant improvement in permeation parameters ex-vivo as 
compared to control. Eucalyptus oil in micro emulsion has important 
role to play in solubilization as well as permeation enhancement of 
hesperidin when applied topically. Conversion of micro emulsion to 
MBO (micro emulsion based ointment) showed significant 
improvement in in-vivo bioavailability as compared to micro 
emulsion. Therefore it is evident that components of ointment 
significantly contributed to the efficient topical delivery of 
hesperidin. Therefore this novel formulation gives insight to the 
topical use of hesperidin with improved bioavailability for the 
treatment of moderate symptoms of venous disease where 
hesperidin reduces capillary permeability. 
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